- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Novopharm fined $1.25 million for contempt of court
In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.
In what may be largest fine ever levied for contempt of court in Canada, courts in Winnipeg penalized Novopharm Ltd. $1.25 million.
Novopharm was fined for failure to comply with a court order to disclose documents pertaining to the drug Lovastatin, for secretly resuming research on the product and for making submissions to the government using illegally retained documents.
According to a statement issued by Associate Chief Justice Oliphant, Novopharm's actions were motivated by a desire to bring Lovastatin to market before rival products, such as those produced by pharmaceutical company Apotex Inc. "The contemptuous conduct here was, I believeâ¦fueled by what must be one of the most bitter business rivalries I have ever witnessed," Oliphant said.
In the past, Novopharm was held liable for misappropriation of technology from a fermentation facility in Winnipeg owned by Apotex.
As a result, Novopharm cannot use the technology and was ordered to pay damages to Apotex in the amount of $6.5 million.
In addition to the most recent fine of $1.25 million, the court also ordered Novopharm to pay all of the legal costs that Apotex incurred as a result of the contempt proceedings. PR
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
